Harrow Inc
Company Profile
Business description
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Contact
1A Burton Hills Boulevard
Suite 200
NashvilleTN37215
USAT: +1 615 733-4730
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
373
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
stocks
Chart of the Week: US equity market trading at an attractive discount
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.90 | 43.80 | 0.48% |
| CAC 40 | 8,203.24 | 60.63 | -0.73% |
| DAX 40 | 23,712.39 | 368.24 | -1.53% |
| Dow JONES (US) | 47,867.32 | 42.60 | -0.09% |
| FTSE 100 | 10,586.43 | 22.45 | -0.21% |
| HKSE | 25,752.40 | 140.62 | -0.54% |
| NASDAQ | 22,571.03 | 63.97 | -0.28% |
| Nikkei 225 | 55,895.32 | 413.10 | -0.73% |
| NZX 50 Index | 13,273.81 | 19.87 | 0.15% |
| S&P 500 | 6,774.43 | 8.38 | -0.12% |
| S&P/ASX 200 | 8,973.20 | 57.80 | 0.65% |
| SSE Composite Index | 3,966.17 | 28.83 | -0.72% |